Login
Search
Search
0 Dates
2024
2023
2022
2021
2020
2019
2018
0 Events
CPC 2018
CPC 2019
Curso de Atualização em Medicina Cardiovascular 2019
Reunião Anual Conjunta dos Grupos de Estudo de Cirurgia Cardíaca, Doenças Valvulares e Ecocardiografia da SPC
CPC 2020
CPC 2021
CPC 2022
CPC 2023
CPC 2024
0 Topics
A. Basics
B. Imaging
C. Arrhythmias and Device Therapy
D. Heart Failure
E. Coronary Artery Disease, Acute Coronary Syndromes, Acute Cardiac Care
F. Valvular, Myocardial, Pericardial, Pulmonary, Congenital Heart Disease
G. Aortic Disease, Peripheral Vascular Disease, Stroke
H. Interventional Cardiology and Cardiovascular Surgery
I. Hypertension
J. Preventive Cardiology
K. Cardiovascular Disease In Special Populations
L. Cardiovascular Pharmacology
M. Cardiovascular Nursing
N. E-Cardiology / Digital Health, Public Health, Health Economics, Research Methodology
O. Basic Science
P. Other
0 Themes
01. History of Cardiology
02. Clinical Skills
03. Imaging
04. Arrhythmias, General
05. Atrial Fibrillation
06. Supraventricular Tachycardia (non-AF)
07. Syncope and Bradycardia
08. Ventricular Arrhythmias and Sudden Cardiac Death (SCD)
09. Device Therapy
10. Chronic Heart Failure
11. Acute Heart Failure
12. Coronary Artery Disease (Chronic)
13. Acute Coronary Syndromes
14. Acute Cardiac Care
15. Valvular Heart Disease
16. Infective Endocarditis
17. Myocardial Disease
18. Pericardial Disease
19. Tumors of the Heart
20. Congenital Heart Disease and Pediatric Cardiology
21. Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure
22. Aortic Disease
23. Peripheral Vascular and Cerebrovascular Disease
24. Stroke
25. Interventional Cardiology
26. Cardiovascular Surgery
27. Hypertension
28. Risk Factors and Prevention
29. Rehabilitation and Sports Cardiology
30. Cardiovascular Disease in Special Populations
31. Pharmacology and Pharmacotherapy
32. Cardiovascular Nursing
33. e-Cardiology / Digital Health
34. Public Health and Health Economics
35. Research Methodology
36. Basic Science
37. Miscellanea
0 Resources
Abstract
Slides
Vídeo
Report
CLEAR FILTERS
Dual cardioprotection with betablockers and angiotensin converting enzyme inhibitors/angiotensin receptor blockers improves right and left ventricular systolic function in patients receiving cardiotoxic chemotherapy
Session:
Posters 5 - Écran 05 - IC - Terapêutica
Speaker:
Ana Ferreira
Congress:
CPC 2018
Topic:
D. Heart Failure
Theme:
10. Chronic Heart Failure
Subtheme:
10.4 Chronic Heart Failure – Treatment
Session Type:
Posters
FP Number:
---
Authors:
Ana Ferreira; Guy Lloyd; Simon Woldman; Mark Westwood; Tom Crake; Meredith Maxwell; Luís Lopes; Charlotte Manisty; Arjun Ghosh
Abstract
<p><strong>Introduction: </strong>Cardiotoxicity is a potential side effect of many chemotherapeutic agents. Cardioprotective therapy (CP) [Angiotensin Converting Enzyme Inhibitors (ACEi) or Angiotensin Receptor Blockers (ARB) and/or beta blockers (BB)] may prevent chemotherapy-related left ventricular (LV) dysfunction. Advanced echocardiographic measurements of cardiac function may help guide CP.</p> <p><strong>Methods: </strong>We retrospectively reviewed patients (pts) seen in the Cardio-Oncology service over a 28-month period. We identified 46 pts [57.6±10.9y old, 35 (76.1%) females] who had received potentially cardiotoxic chemotherapy [20 (43.5%) of whom also had radiotherapy] and had at least one echocardiographic evaluation before and another after starting CP. At both time points a full assessment of LV systolic and diastolic function was carried out.</p> <p><strong>Results: </strong>24 pts had breast cancer (52%), 7 lymphoma (15%), 7 myeloma (15%), 4 other haematological (9%) and 4 gastrointestinal malignancies (9%). 15 pts received anthracyclines, 9 trastuzumab, 13 anthracyclines and trastuzumab, while 9 received other chemotherapeutic drugs. 34 patients (73.9%) received dual CP (BB and ACEI/ARB), 8 (17.4%) ACEI/ARB, and 4 (8.7%) BB only. Baseline and follow-up echocardiographic values are shown in table 1. The time interval between assessments was 130.28±99.96days. GLS, LVEF, e’ septal, e’ average and TAPSE significantly improved with dual CP.</p> <p><strong>Conclusions: </strong>Early effects of CP in left and right ventricular function are identifiable by GLS, LVEF, e’ and TAPSE, with dual CP demonstrating an early beneficial effect.</p> <p> </p>
Our mission: To reduce the burden of cardiovascular disease
Visit our site